Publications

Jonathan Himmelfarb, MD

  1. Mahoney, RJ, Ault, KA, Given, SR, Adams, RJ, Breggia AC, Paris, PA, Palomaki, GE, Hitchcox, S, Fuller, T, White BW, Himmelfarb, J, Leeber, DA: The Flow Cytometric Crossmatch and Early Renal Transplant Loss. Transplantation, 49:527-535, 1990.
  2. Hakim, RM, Milford, E, Himmelfarb, J, Wingard, R, Lazarus, JM, Watt RM: Extracorporeal Removal of Anti-HLA Antibodies in Transplant Candidates. Am J Kidney Dis, XVI:5, 423-431, 1990.
  3. Himmelfarb, J, Hakim, RM, Lazarus, JM: Reactive Oxygen Species Production by Monocytes and Polymorphonuclear Leukocytes During Dialysis. Am J Kidney Dis, XVII:3, 271-276, 1991.
  4. Himmelfarb, J, Hakim, RM, Gerard, NS, Lazarus, JM: Intradialytic Modulation of Granulocyte C5a Receptors. J Am Soc Nephrol, 2:920-926, 1991.
  5. Himmelfarb, J, Hakim, RM, Holbrook, D, Leeber, DA, Ault, KA: Detection of Granulocyte Reactive Oxygen Species Formation in Whole Blood Using Flow Cytometry. Cytometry, 13:83-89, 1992.
  6. Himmelfarb, J, Zaoui, P, Holbrook, D, Hakim RM: Modulation of Granulocyte LAM1 and MAC1 During Dialysis - A Prospective, Randomized Controlled Trial. Kidney Int, 41:388-395, 1992.
  7. Himmelfarb, J, Ault KA, Holdbrook D, Leeber DA, Hakim RM: Intradialytic Granulocyte Reactive Oxygen Species Production: A Prospective Crossover Trial. J Am Soc Nephrol, 4:178-186, 1993.
  8. Sreedhara R, Himmelfarb, J, Lazarus JM, Hakim RM: Anti-platelet Therapy in Graft Thrombosis: Results of a Prospective, Randomized, Double-blind Study. Kidney Int, 45:1477-1483, 1994.
  9. Himmelfarb, J, Holbrook D, McMonagle E, Robinson, R, Nye, L, Spratt, D: Kt/V, Nutritional Parameters, Serum Cortisol and IGF-1 Levels and Patient Outcome in Hemodialysis. Am J Kidney Dis, 24:473-479, 1994.
  10. Himmelfarb, J, Holbrook D, McMonagle E: Effects of Aprotinin on Complement and Granulocyte Activation During Ex Vivo Hemodialysis. Am J Kidney Dis, 24:901-906, 1994.
  11. Himmelfarb, J, McMonagle E, Holbrook D, Toth C: Soluble CR1 Inhibits both Complement and Granulocyte Activation During Ex Vivo Hemodialysis. J Lab Clin Med, 126:392-400, 1995.
  12. Himmelfarb, J, Connerney M, Mitchell J, Knowles C, Hillman RS, Ault KA: Increased Transferrin Receptors Expression on Reticulocytes is an Early Indicator of Response to Erythropoietin. Laboratory Hematology, 1:105-111, 1995.
  13. Conger JD, Allgren RL, Miller SB, Himmelfarb, J: Clinical Trials in the Clinical Care Setting. J Nephrol, 9(4):1-7, 1996.
  14. Himmelfarb, J, Couper L, Eldrup-Jorgensen J: Dipyridamole Inhibits PDGF and bFGF-Induced Vascular Smooth Muscle Cell Proliferation. Kidney Int, 52:1671-1677, 1997.
  15. Himmelfarb, J, Couper L: Dipryidamole inhibits PDGF- and bFGF-induced vascular smooth muscle cell proliferation. Kidney Int, 52:1671-1677, 1997.
  16. Himmelfarb, J, Holbrook D, McMonagle E, Ault K: Increased reticulated platelets in dialysis patients. Kidney Int, 51:834-839, 1997.
  17. Neyra NR, Ikizler TA, May RE, Himmelfarb, J, Schulman G, Shyr Y, Hakim RM: Change in access blood flow over time predicts vascular access thrombosis. Kidney Int, 54:1714-1719, 1998.
  18. Himmelfarb, J, Tolkoff-Rubin N, Chandran P, Parker R, Wingard RL, Hakim R: A multicenter comparison of dialysis membranes in the treatment of acute renal failure requiring dialysis. J Am Soc Nephrol, 9:257-266, 1998.
  19. Parker RA, Himmelfarb, J, Tolkoff-Rubin N, Chandran P, Wingard RL, Hakim RM: Prognosis of Patients with Acute Renal Failure Requiring Dialysis: Results of a Multi-Center Study. Am J Kidney Dis, 32(2):432-443, 1998.
  20. Evanson JA, Himmelfarb, J, Wingard R, Knights S, Shyr Y, Schulman G, Ikizler TA, Hakim RM: Prescribed versus delivered dialysis in acute renal failure patients. Am J Kidney Dis, 32(5):731-738, 1998.
  21. Himmelfarb, J, McMonagle E, Holbrook D, Hakim R: Increased susceptibility to erythrocyte C5b-9 deposition and complement-mediated lysis in chronic renal failure. Kidney Int, 55:659-666, 1999.
  22. Delmonico FL, Harmon WE, Lorber MI, Goguen J Mah, H, Himmelfarb, J, Lipkowitz G, Valliere S, Bow L, Milford EL, Rohrer RJ: A New Allocation Plan for Renal Transplantation. Transplantation Proceedings, 31:358-359, 1999.
  23. Delmonico FL, Harmon WE, Lorber MI, Goguen J, Mah H, Himmelfarb, J, Lipkowitz G, Valliere S, Bow L, Milford EL, Rohrer RJ: A New Allocation Plan for Renal Transplantation. Transplantation, 67(2):303-309, 1999.
  24. Himmelfarb, J, Couper L: Dipyridamole Inhibits Vascular Smooth Muscle Cell Proliferation by Reducing GI Cell Cycle Arrest. Blood Purif, (suppl 1)2-66:3-4, 1999.
  25. Saadeh E, Szatkowski M, Vary CPH, Smith JD, Himmelfarb, J, Mahoney RJ: HLA DMA Allele Polymorphism: No Impact on Kidney Allograft Outcome. Human Immunology, 61:345-347, 2000.
  26. Himmelfarb J, McMonagle E, McMenamin E: Plasma Protein Thiol Oxidation and Carbonyl Formation in Chronic Renal Failure. Kidney Int, 58:2571-2578, 2000.
  27. Himmelfarb J, McMonagle E: Manifestations of Oxidant Stress in Uremia. Blood Purif, 19:200-205, 2001.
  28. Himmelfarb J, McMonagle E: Albumin is the Major Plasma Protein Target of Oxidant Stress in Uremia. Kidney Int, 60:358-363, 2001.
  29. Saadeh E, Ikizler TA, Shyr Y, Hakim RM, Himmelfarb J: Recombinant Human Growth Hormone in Patients with Acute Renal Failure. Journal of Renal Nutrition, 11(4):212-219, 2001.
  30. Himmelfarb J, McMenamin E, Loseto G, Heineke JW: Myeloperoxidase-catalyzed 3-chlorotyrosine formation in dialysis patients. Free Radical Biology & Medicine, 31(10):1163-1169, 2001.
  31. Himmelfarb J, Evanson J, Hakim RM, Freedman S, Shyr Y, Ikizler TA: Urea volume of distribution exceeds total body water in patients with acute renal failure. Kidney International, 61(1):317-323, 2001.
  32. DeMars CS, Hollister K, Tomassoni A, Himmelfarb J, Halperin, ML: Citric Acid Indigestion - A Life-threatening Cause of Metabolic Acidosis. Annals of Emergency Medicine, 38(5):588-591, 2001.
  33. Himmelfarb J, McMenamin E, McMonagle E: Plasma aminothiol oxidation in chronic hemodialysis patients. Kidney International, 61(2):705-716, 2002.
  34. Ikizler TA, Morrow JD, Roberts LJ, Evanson JA, Becker B, Hakim RM, Shyr Y, Himmelfarb J: Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients. Clin.Nephrol 58:190-197, 2002
  35. Chertow GM, Pascual MT, Soroko S, Savage BR, Himmelfarb J, Ikizler TA, Paganini EP, Mehta RL: Reasons for non-enrollment in a cohort study of ARF: the Program to Improve Care in Acute Renal Disease (PICARD) experience and implications for a clinical trials network. Am J Kidney Dis 42:507-512, 2003.
  36. Himmelfarb J, Kane J, McMonagle E, Zaltas E, Bobzin S, Boddupalli S, Phinney S, Miller G: Alpha and gamma tocopherol metabolism in healthy subjects and patients with end-stage renal disease. Kidney Int 64:978-991, 2003.
  37. Danielski M, Ikizler TA, McMonagle E, Kane JC, Pupim L, Morrow J, Himmelfarb J: Linkage of hypoalbuminemia, inflammation, and oxidative stress in patients receiving maintenance hemodialysis therapy. Am J Kidney Dis 42:286-294, 2003.
  38. Vannorsdall MD, Arkel YS, Ku DH, Lucas FL, Himmelfarb J: Perioperative topical bovine thrombin exposure is not associated with hemodialysis graft thrombosis. Kidney Int 64:690-696, 2003.
  39. Pupim, LB, Himmelfarb J, McMonagle, Shyr EY, Ikizler TA: Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. Kidney Int. 65:2371-2379, 2004.
  40. Mehta RL, Pascual MT, Soroko S, Savage SBR, Himmelfarb J, Ikizler TA, Paganini PA, Chertow GM. Spectrum of acute renal failure in the intensive care unit: The PICARD experience. Kidney Int. 66:1613-1621, 2004
  41. Delmonico FL, Morrissey PE, Lipkowitz GS, Stoff, JS, Himmelfarb J, et al: Donor kidney exchanges. Am J Transplant. 4:1628-1634, 2004.
  42. Himmelfarb J, McMonagle E, Freedman S, Klenzak J, McMenamin E, Le P, Pupim LB, Ikizler TA, The PICARD Group: Oxidative stress is increased in critically ill patients with acute renal failure. J Am Soc Nephrol 15:2449-2456, 2004.
  43. Deitcher, SR., Fraschini G, Himmelfarb J, et al: Dose-ranging trial with a recombinant urokinase (urokinase alfa) for occluded central venous catheters in oncology patients. J Vasc.Interv.Radiol. 15:575-580, 2004.
  44. Simmons, E M, Himmelfarb J, et al. 2004. Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int. 65:1357-1365, 2004
  45. Parker, TF, Blantz R, Hostetter T, Himmelfarb J, et al: The chronic kidney disease initiative. J Am Soc Nephrol 15:708-716, 2004.
  46. Oberg, BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, Himmelfarb J: Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 65:1009-1016, 2004.
  47. Ikizler, TA, Sezer MT, Flakoll PJ, Hariachar S, Kanagasundaram NS, Gritter N, Knights S, Shyr R, Paganini, E, Hakim RM, Himmelfarb J: Urea space and total body water measurements by stable isotopes in patients with acute renal failure. Kidney Int. 65:725-732, 2004.
  48. Himmelfarb J, McMonagle E, Freedman S, Klenzak J, McMenamin E, Le P, Pupim LB, Ikizler TA, and the PICARD Group: Oxidative stress is increased in critically ill patients with acute renal failure. J Am Soc Nephrol, 15:2449-2456, 2004.
  49. Himmelfarb J, Le P, Klenzak J, et al: Impaired monocyte cytokine production in critically ill patients with acute renal failure. Kidney Int 66:2354-2360, 2004.
  50. Himmelfarb J, Pereira BJG, Wesson DE, Smedberg PC, Henrich WL: Payment for quality in end stage renal disease. J Am Soc Nephrol 15:3263-3269, 2004.
  51. Basi S, Pupim LB, Simmons EM, Sezer MT, Shyr Y, Freedman S, Chertow GM, Mehta RL, Paganini E, Himmelfarb J, Ikizler TA. Insulin Resistance in Critically Ill Patients with Acute Renal Failure. Am J Physiol Renal Physiol. 2005 Apr 19; Epub ahead of print.
  52. Simmons EM, Langone A, Sezer MT, Vella JP, Recupero P, Morrow JP, Ikizler TA, Himmelfarb J: Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients. Transplantation 79:914-919, 2005.
  53. Boaz M, Iuliano L, Himmelfarb J et al: Baseline Oxysterols and Other Markers of Oxidative Stress, Inflammation and Malnutrition in the Vitamin E and Intima Media Thickness Progression in End-Stage Renal Disease (VIPER) Cohort. Nephron Clin Pract 100:c111-c119, 2005.
  54. Himmelfarb J: Relevance of oxidative pathways in the pathophysiology of chronic kidney disease. Cardiol Clin 23:319-330, 2005
  55. Himmelfarb J: Hemodialysis complications. Am J Kidney Dis 45:1122-1131, 2005.
  56. Reddan DN, Szczech LA, Hasselblad V, Lowrie EG, Lindsay RM, Himmelfarb J, Toto RD, Stivelman J, Winchester JF, Zillman LA, Califf RM, Owen WF Jr: Intradialytic blood volume monitoring in ambulatory hemodialysis patients: a randomized trial. J Am Soc Nephrol 16:2162-2169, 2005.
  57. Simmons EM, Langone A, Sezer MT, Vella JP, Recupero P, Morrow JD, Ikizler TA, Himmelfarb J: Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients. Transplantation 79:914-919, 2005.
  58. Schimelman B, Zimmerman R, Himmelfarb J: What is the Current and Future Status of Interventional Nephrology? Semin Dial 18:375-377, 2005.
  59. Klenzak J, Himmelfarb J: Sepsis and the kidney. Crit Care Clin 21:211-222, 2005.